MicroRNA profile in stage I clear cell renal cell carcinoma predicts progression to metastatic disease.
Adult
Aged
Biomarkers, Tumor
/ analysis
Carcinoma, Renal Cell
/ diagnosis
Disease Progression
Female
Follow-Up Studies
Gene Expression Profiling
Gene Expression Regulation, Neoplastic
Humans
Kaplan-Meier Estimate
Kidney
/ pathology
Kidney Neoplasms
/ diagnosis
Male
MicroRNAs
/ analysis
Middle Aged
Neoplasm Grading
Neoplasm Staging
Nephrectomy
Oligonucleotide Array Sequence Analysis
Predictive Value of Tests
Prognosis
Risk Assessment
/ methods
Biomarkers
Clear cell renal cell cancer (ccRCC)
Metastasis
Progression
microRNA
Journal
Urologic oncology
ISSN: 1873-2496
Titre abrégé: Urol Oncol
Pays: United States
ID NLM: 9805460
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
23
03
2020
revised:
29
04
2020
accepted:
09
05
2020
pubmed:
15
6
2020
medline:
29
6
2021
entrez:
15
6
2020
Statut:
ppublish
Résumé
This study sought to identify microRNA (miRNA) profiles of small, pathologically confirmed stage 1 clear cell renal cell carcinoma (ccRCC) tumors that are associated with progression to metachronous metastatic disease. Fifty-five pathologic stage 1 ccRCC tumors ≤5cm, from 2 institutions, were examined in a miRNA screening, followed by a validation study. For the screening phase 752 miRNA were evaluated on each sample to identify those with differential expression between tumors that subsequently did (n = 10) or did not (n = 10) progress to metastatic disease. For the validation, 35 additional samples (20 nonprogressors and 15 with distant progression) were utilized to investigate 20 miRNA to determine if a miRNA panel could differentiate aggressive tumors: associations of miRNA expression with cancer specific survival was also investigated. In the screening analysis, 35 miRNA were differentially expressed (P < 0.05, FDR < 0.1) between the groups. In the validation, 11 miRNA were confirmed to have differential expression. The miRNA -10a-5p, -23b-3p, and -26a-5p differentiated nonprogressive and distant progressive disease with a sensitivity of 73.3% and a specificity of 85% (AUC=0.893). In addition, levels of miR-30a-3p and -145-5p were identified as independent prognostic factors of cancer specific survival. This investigation identified miRNA biomarkers that may differentiate between non-progressive ccRCC tumors and those that progress to metastatic disease in this group of stage I tumors. The miRNA profiles determined in this study have the potential to identify patients with small renal masses who are likely to have progressive ccRCC. Such information may be valuable to incorporate into predictive models.
Identifiants
pubmed: 32534961
pii: S1078-1439(20)30210-6
doi: 10.1016/j.urolonc.2020.05.006
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
MicroRNAs
0
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
799.e11-799.e22Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.